Crizotinib (PF-02341066)

Name: Crizotinib (PF-02341066)
Brand: Selleck Chemicals
SKU: S1068
Rating: 5 (334 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1068

334 publications

Crizotinib (PF-02341066) Chemical Structure

CAS No. 877399-52-5

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.

Selleck's Crizotinib (PF-02341066) has been cited by 334 publications

Cell, 2021, 184(10):2649-2664.e18

PubMed: 33848463 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 174(4):856-869

PubMed: 30096312 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nat Med, 2015, 21(9):1038-47

PubMed: 26301689 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Cancer Discov, 2015, 10.1158/2159-8290.CD-15-0913

PubMed: 26566875 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2014, 4(12):1398-405

PubMed: 25266736 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Nat Med, 2012, 18(6):883-91

PubMed: 22635005 ( click the link to review the publication )

Nat Med, 2011, 17(9):1116-20

PubMed: 21822287 ( click the link to review the publication )

Cancer Cell, 2011, 19(5):679-90

PubMed: 21575866 ( click the link to review the publication )

Cancers (Basel), 2021, 13(3)E372

PubMed: 33498427 ( click the link to review the publication )
Cancers (Basel), 2021, 13(16)4133

PubMed: 34439291 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0965.2020

PubMed: 34158345 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0221.2021

PubMed: 34158340 ( click the link to review the publication )

J Mol Biol, 2021, 433(19):167158

PubMed: 34273398 ( click the link to review the publication )

Cancer Sci, 2021, 112(5):1853-1864

PubMed: 33410241 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):25

PubMed: 33677467 ( click the link to review the publication )

Oncogenesis, 2021, 10(3):27

PubMed: 33712563 ( click the link to review the publication )

Front Oncol, 2021, 11:650052

PubMed: 34094940 ( click the link to review the publication )

Biochem Pharmacol, 2021, 190:114620

PubMed: 34043966 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9011

PubMed: 33907223 ( click the link to review the publication )

Sci Rep, 2021, 11(1):12466

PubMed: 34127734 ( click the link to review the publication )

Sci Rep, 2021, 11(1):9587

PubMed: 33953226 ( click the link to review the publication )

Mol Carcinog, 2021, 60(7):481-496

PubMed: 34018249 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

BMC Cancer, 2021, 21(1):310

PubMed: 33761896 ( click the link to review the publication )

Ann Hematol, 2021, 10.1007/s00277-020-04357-z

PubMed: 34110462 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2021, 53(7):823-836

PubMed: 33961012 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Angiogenesis, 2021, 10.1007/s10456-021-09771-z

PubMed: 33629198 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):78

PubMed: 34404896 ( click the link to review the publication )

NPJ Breast Cancer, 2021, 7(1):60

PubMed: 34040000 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5704

PubMed: 33177525 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5017

PubMed: 33024122 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )
Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Dev Cell, 2020, 4;53(3):344-357 e5

PubMed: 32302545 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-3608

PubMed: 32034073 ( click the link to review the publication )

Clin Cancer Res, 2020, 8

PubMed: 32269053 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Cancer Res, 2020, canres.1992.2020

PubMed: 33203698 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2697

PubMed: 32967224 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):882

PubMed: 33082316 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Cancer Discov, 2020, 1 pii: CD-19-1030

PubMed: 32238360 ( click the link to review the publication )

Front Immunol, 2020, 11:527750

PubMed: 33324391 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1810-1821

PubMed: 33209603 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):403-423

PubMed: 32195017 ( click the link to review the publication )

Oral Oncol, 2020, 112:105074

PubMed: 33142224 ( click the link to review the publication )

Lung Cancer, 2020, 144:20-29

PubMed: 32353632 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

J Cell Sci, 2020, 11;133(9) pii: jcs241505

PubMed: 32184261 ( click the link to review the publication )
Antiviral Res, 2020, 178:104790

PubMed: 32272175 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(14):2595-2611

PubMed: 32792859 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015891

PubMed: 33087447 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00513-3

PubMed: 32918045 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020,

PubMed: 32874131 ( click the link to review the publication )

Oncol Rep, 2020, 43(3):817-826

PubMed: 32020234 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:2046248

PubMed: 33376716 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(1):109-119

PubMed: 31892559 ( click the link to review the publication )

Anticancer Res, 2020, 40(3):1395-1403

PubMed: 32132036 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

NPJ Precis Oncol, 2020, 4:21

PubMed: 32802958 ( click the link to review the publication )

Hemasphere, 2020, 4(6):e497

PubMed: 33196013 ( click the link to review the publication )

Neoplasia, 2020, 22(10):470-483

PubMed: 32818841 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Oncogenesis, 2020, 9(7):64

PubMed: 32632141 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3991

PubMed: 31488816 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4343

PubMed: 31554817 ( click the link to review the publication )
Clin Cancer Res, 2019, clincanres.1486.2019

PubMed: 31636099 ( click the link to review the publication )

EMBO Mol Med, 2019, 10.15252/emmm.201910581

PubMed: 31633304 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1667

PubMed: 31548343 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Cancer Res, 2019, 79(3):546-556

PubMed: 30538120 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-1104

PubMed: 31585938 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Oncogene, 2019, 101038/s41388-019-1136-4

PubMed: 31804622 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

EBioMedicine, 2019, 42:326-339

PubMed: 30879923 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31072019 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E104

PubMed: 30658414 ( click the link to review the publication )

Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Cell Death Dis, 2019, 10(2):139

PubMed: 30760701 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(3):718-725

PubMed: 30755456 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31334113 ( click the link to review the publication )

Front Oncol, 2019, 9:579

PubMed: 31380285 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 166:128-138

PubMed: 31078602 ( click the link to review the publication )

Toxicol Sci, 2019, 10.1093/toxsci/kfz123

PubMed: 31132080 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(17)

PubMed: 31480591 ( click the link to review the publication )
Sci Rep, 2019, 9(1):19353

PubMed: 31852910 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 383:114768

PubMed: 31639374 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-019-00795-3

PubMed: 31124056 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1044

PubMed: 31690270 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):1231-1240

PubMed: 30653748 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(2):260-265

PubMed: 30791979 ( click the link to review the publication )

Future Oncol, 2019, 15(22):2585-2593

PubMed: 31339066 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31540894 ( click the link to review the publication )

Oncotarget, 2019, 10(65):6981-6996

PubMed: 31857852 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(10):1753-1765

PubMed: 31279006 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(8):768-777

PubMed: 29942081 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4086-4097

PubMed: 29990309 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Leukemia, 2018, 32(9):1994-2007

PubMed: 29588546 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cell Syst, 2018, 6(3):329-342

PubMed: 29550255 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(12):2732-2739

PubMed: 29559559 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cell Death Differ, 2018, 25(12):2053-2070

PubMed: 29515255 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459283 ( click the link to review the publication )

Sci Signal, 2018, 11(557)eaar5680

PubMed: 30459281 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):974

PubMed: 30250188 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(11-:2271-2284

PubMed: 30135214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):931-942

PubMed: 29440449 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):222-231

PubMed: 29054983 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

Front Oncol, 2018, 8:460

PubMed: 30464927 ( click the link to review the publication )

Sci Rep, 2018,

PubMed: 29849102 ( click the link to review the publication )

Cancer Gene Ther, 2018, 26(1-2):1-10

PubMed: 29925897 ( click the link to review the publication )

Cancer Discov, 2018, 8(6):714-729

PubMed: 29650534 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Cancer Res Treat, 2018, 50(2):599-613

PubMed: 28675026 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 82(2):251-263

PubMed: 29855693 ( click the link to review the publication )

Pediatr Blood Cancer, 2018, 65(8):e27094

PubMed: 29697184 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):5983-5991

PubMed: 30333869 ( click the link to review the publication )
Oncol Lett, 2018, 16(5):5992-5996

PubMed: 30333870 ( click the link to review the publication )

Oncotarget, 2018, 9(43-:27242-27255

PubMed: 29930762 ( click the link to review the publication )

Oncolytic Virother, 2018, 7:107-116

PubMed: 30538967 ( click the link to review the publication )

J Thorac Oncol, 2017, S1556-0864(17)30365-9

PubMed: 28502721 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3502-3512

PubMed: 28512244 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Oncogene, 2017,

PubMed: 28759046 ( click the link to review the publication )

Oncogene, 2017, 36(38):5407-5420

PubMed: 28534512 ( click the link to review the publication )

J Pathol, 2017, 243(3):307-319

PubMed: 28741662 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3013

PubMed: 28837150 ( click the link to review the publication )

Br J Cancer, 2017, 117(12):1787-1797

PubMed: 29024938 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Oncologist, 2017, 22(2):158-164

PubMed: 28167572 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Am J Cancer Res, 2017, 7(2):203-217

PubMed: 28337371 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):191

PubMed: 28292264 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Molecules, 2017, 22(12)

PubMed: 29206199 ( click the link to review the publication )

Medchemcomm, 2017, 8(10):1914-1918

PubMed: 30108712 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Oncol Lett, 2017, 13(6):4085-4092

PubMed: 28599410 ( click the link to review the publication )

Cardiooncology, 2017, 3

PubMed: 28217366 ( click the link to review the publication )
Oncotarget, 2017, 8(70):114945-114955

PubMed: 29383132 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51675-51687

PubMed: 28881678 ( click the link to review the publication )

Blood, 2016, 128(9):1234-45

PubMed: 27297792 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

J Clin Invest, 2016, 3;126(10):3739-3757

PubMed: 27571409 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(7):1787-99

PubMed: 26667487 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(22):5527-5538

PubMed: 27780853 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(24):6031-6038

PubMed: 27091406 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1506-16

PubMed: 26719536 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27197184 ( click the link to review the publication )

Cancer Res, 2016, 76(4):974-83

PubMed: 26837769 ( click the link to review the publication )

Elife, 2016, 5e12116

PubMed: 26987019 ( click the link to review the publication )

J Pathol, 2016, 238(4):543-9

PubMed: 26606880 ( click the link to review the publication )

Cancer Discov, 2016, 6(12):1334-1341

PubMed: 27694386 ( click the link to review the publication )

Oncoimmunology, 2016, 5(3):e1094598

PubMed: 27141355 ( click the link to review the publication )

Oncoimmunology, 2016,

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):3040-3054

PubMed: 27612490 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2236-2244

PubMed: 27748834 ( click the link to review the publication )
Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Endocrine, 2016, 53(1):145-56

PubMed: 26370117 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(3):623-8

PubMed: 26849637 ( click the link to review the publication )

PLoS One, 2016, 11(11):e0165983

PubMed: 27832137 ( click the link to review the publication )

Vet Parasitol, 2016, 227:64-8

PubMed: 27523939 ( click the link to review the publication )

Int J Surg, 2016, 28:179-84

PubMed: 26957017 ( click the link to review the publication )

World J Clin Oncol, 2016, 7(6):425-432

PubMed: 28008383 ( click the link to review the publication )

Sci Rep, 2016, 10.1038/srep24817

PubMed: 27102549 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84675-84687

PubMed: 27835869 ( click the link to review the publication )

Springerplus, 2016, 5:348

PubMed: 27057482 ( click the link to review the publication )

Sci Rep, 2016, 6:32992

PubMed: 27623107 ( click the link to review the publication )

Tumour Biol, 2016, 37(4):4373-82

PubMed: 26499783 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75968-75980

PubMed: 27732954 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29199-210

PubMed: 27078848 ( click the link to review the publication )

Oncotarget, 2016, 7(5):5646-63

PubMed: 26735175 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(17):23715-29

PubMed: 27009859 ( click the link to review the publication )

Blood, 2015, 126(26):2821-31

PubMed: 26531163 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-15-0370

PubMed: 25952648 ( click the link to review the publication )

Cancer Res, 2015, 75(14):2916-27

PubMed: 26018086 ( click the link to review the publication )

Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

PLoS Genet, 2015, 11(9):e1005533

PubMed: 26393505 ( click the link to review the publication )
Cancer Discov, 2015,

PubMed: 26432108 ( click the link to review the publication )

Oncoimmunology, 2015, 5(3):e1108514

PubMed: 27141364 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11-:2433-40

PubMed: 26351321 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Radiother Oncol, 2015,

PubMed: 25592111 ( click the link to review the publication )

Radiother Oncol, 2015, 114(2):173-81

PubMed: ( click the link to review the publication )

Cancer Sci, 2015, 106(3):244-52

PubMed: 25581823 ( click the link to review the publication )

Lung Cancer, 2015, 90(3):590-7

PubMed: 26547802 ( click the link to review the publication )

J Cell Physiol, 2015, 230(9):2281-98

PubMed: 25704960 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1025-30

PubMed: 25502629 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):122-32

PubMed: 25955731 ( click the link to review the publication )

BMC Cancer, 2015, 15:451

PubMed: 26036285 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0132330

PubMed: 26147305 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0124283

PubMed: 25919140 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0121378

PubMed: 25874976 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:375-83

PubMed: 25678804 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 10.1016/j.bbrc.2015.02.114

PubMed: 25735977 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31640-58

PubMed: 26436697 ( click the link to review the publication )

Oncotarget, 2015, 6(27):24320-32

PubMed: 26172300 ( click the link to review the publication )

Cell, 2015, 162(6):1271-85

PubMed: 26359985 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2015, 18(6):330-9

PubMed: 26104888 ( click the link to review the publication )
Oncotarget, 2015, 6(14):11820-32

PubMed: 25909220 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26375439 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40268-82

PubMed: 26384345 ( click the link to review the publication )

Oncotarget, 2015, 6(30):28774-89

PubMed: 26299615 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: 25144242 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(11):1638-46

PubMed: ( click the link to review the publication )

J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(44):E4706-15

PubMed: 25331893 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Elife, 2014, 10.7554/eLife.03751

PubMed: 25551293 ( click the link to review the publication )

Cancer Lett, 2014, 351(2):215-21

PubMed: 24887559 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(1):134-43

PubMed: 24170771 ( click the link to review the publication )

Mol Cancer Ther, 2014, 10.1158/1535-7163.MCT-14-0274

PubMed: 25349307 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Cancer Sci, 2014, 105(5):528-36

PubMed: 24612061 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: 25426675 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2014, 140(4):589-98

PubMed: 24509625 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2014, 74(5):1023-8

PubMed: 25205428 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112148

PubMed: 25386922 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )
Biomed Res Int, 2014, 2014:764981

PubMed: 25057499 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.10.126

PubMed: ( click the link to review the publication )

Jpn J Clin Oncol, 2014, 44(10):963-8

PubMed: 25170107 ( click the link to review the publication )

Future Oncol, 2014, 10(2):211-7

PubMed: 24490607 ( click the link to review the publication )

Leuk Res, 2014, 38(4):503-8

PubMed: 24486291 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014, 5(13):4920-8

PubMed: 24952482 ( click the link to review the publication )

Urol Oncol, 2014, 32(6):877-84

PubMed: 24929890 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):427-36

PubMed: 23335077 ( click the link to review the publication )

Int J Cancer, 2013, 132(2):E74-84

PubMed: 22948846 ( click the link to review the publication )

Br J Cancer, 2013, 109(12):3084-91

PubMed: 24149177 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

PLoS Genet, 2013, 9(11):e1003958

PubMed: 24278035 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1093-102

PubMed: 23993685 ( click the link to review the publication )

ACS Chem Biol, 2013, 9(3):777-84

PubMed: 24397822 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(6):e000376

PubMed: 24308935 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1640-6

PubMed: 24118504 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Sci Rep, 2013, 3:3450

PubMed: 24356251 ( click the link to review the publication )

Int J Cardiol, 2013, 168(4):3486-94

PubMed: 23680593 ( click the link to review the publication )

Mol Pharmacol, 2013, 83(4):882-93

PubMed: 23371912 ( click the link to review the publication )

Clin Chem Lab Med, 2013, 51(9):1843-8

PubMed: 23612660 ( click the link to review the publication )
Toxicol Appl Pharmacol, 2013, 272(1):245-55

PubMed: 23707608 ( click the link to review the publication )

J Cell Biochem, 2013, 114(4):816-22

PubMed: 23060267 ( click the link to review the publication )

Molecules, 2013, 18(12):15412-21

PubMed: 24335618 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56010

PubMed: 23418494 ( click the link to review the publication )

Oncotarget, 2013, 4(12):2237-48

PubMed: 24163262 ( click the link to review the publication )

Tumour Biol, 2013, 35(4):3229-35

PubMed: 24293393 ( click the link to review the publication )

Springerplus, 2013, 2:497

PubMed: 24102046 ( click the link to review the publication )

CELON PHARMA, 2013, 2013

PubMed: ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(5):1669-83

PubMed: 22233293 ( click the link to review the publication )

Neoplasia, 2012, 14(7):572-84

PubMed: 22904675 ( click the link to review the publication )

ACS Chem Biol, 2012, 7(8):1429-35

PubMed: 22625864 ( click the link to review the publication )

J Biol Chem, 2012, 287(18):14586-97

PubMed: 22418436 ( click the link to review the publication )

J Biol Chem, 2012, 287(47):39812-23

PubMed: 23024367 ( click the link to review the publication )

PLoS One, 2012, 7(2):e30820

PubMed: 22319590 ( click the link to review the publication )

Pediatr Blood Cancer, 2012, 17(23):7394-401

PubMed: 22488797 ( click the link to review the publication )

Clin Cancer Res, 2011, 59(3):440-7

PubMed: 21948233 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5255-64

PubMed: 21697284 ( click the link to review the publication )

J Biomol Screen, 2011, 16(2):141-54

PubMed: 21297102 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective c-Met Inhibitors

Biological Activity

Description

Targets

ROS1 ^[6] (Cell-free assay)	c-Met ^[1] (A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)	ALK ^[1] (Karpas299 cells)
<0.025 nM(Ki)	11 nM	24 nM

In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. ^[1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. ^[2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SU-DHL1	MmrzR5l1d3SxeHnjJGF{e2G7				NFjNWIZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUXS2GSFyxJINmdGy\|IHX4dJJme3OrbnegRWxMKGOxZYjwdoV{e2mwZzDOVG0hf2m2aDDJR\|UxKG:oIECuNFEh\|ryP	M3iz[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
BAF3	NET3eHpEgXSxdH;4bYMhSXO\|YYm=		NVXW[4RuPDhiaB?=	M2\FPWROW09?	M4e5bmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugSlEyPzSOIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNE43OiEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
BAF3	M1nycGN6fG:2b4jpZ{BCe3OjeR?=		MXu0PEBp	NIDwUY9FVVOR	M135dmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
BAF3	NVu3NW95S3m2b4TvfIlkKEG\|c3H5		NIfYVHQ1QCCq	M3\5VGROW09?	M1TyV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyC5aYToJGlEPTBib3[gNE4zQCEQvF2=	NWPBOJVoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1O\|I2QDlpPkKxOVczPTh7PD;hQi=>
Kelly	NInZUIdEgXSxdH;4bYMhSXO\|YYm=			M1vIb2ROW09?	NHzIZ4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBM\WyueTDj[YxteyCneIDy[ZN{cW6pIFHMT{BHOTF5NFygcZV1[W62IIfpeIghUUN3MDDv[kAxNjR{IN88US=>	M1mxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUeyOVg6Lz5{MUW3NlU5QTxxYU6=
SH-SY5Y	M2XVN2N6fG:2b4jpZ{BCe3OjeR?=			M1j2eGROW09?	NHi1boJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUC2VWUXZJINmdGy\|IHX4dJJme3OrbnegRWxMKEZzMUe0UEBufXSjboSge4l1cCCLQ{WwJI9nKDBwNUOg{txO	NHvPXJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW3NlU5QSd-MkG1O\|I2QDl:L3G+
SMS-KCN	NX;OVYRMS3m2b4TvfIlkKEG\|c3H5			MV3EUXNQ	NXzvXG55S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO\|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>?	Mk\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3N{K1PFkoRjJzNUeyOVg6RC:jPh?=
BAF3	NXvU[ItUS3m2b4TvfIlkKEG\|c3H5		M4HPTFQ5KGh?	NEHWenJFVVOR	NX[4N2FES3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTV5MkW4PUc,OjF3N{K1PFk9N2F-
3T3	NHqzcYNHfW6ldHnvckBCe3OjeR?=		MXOxJIg>	MmC1SG1UVw>?	NWXRSodsUW6qaXLpeIlwdiCxZjDSU24h[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFgh\|ryP	M3HhWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
3T3-E	NXPxW4VVTnWwY4Tpc44hSXO\|YYm=		M1;iblEhcA>?	MVLEUXNQ	MVvJcohq[mm2aX;uJI9nKFSLRUKgZZN{\XO\|ZXSg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvPDR6IN88US=>	NVjrSnVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OTRpPkKxPFEzPDF2PD;hQi=>
A549	MUDLbY5ie2ViQYPzZZk>		NWT1elcyOSCq	NWDGSWpZTE2VTx?=	NEnHSlNKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IHOtUWVVKGurbnHz[UBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBJT0ZvaX7keYNm\CCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjByODFOwG0>	NFjrd5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
BAF3-BCL	MY\GeY5kfGmxbjDBd5NigQ>?		Mk\lNUBp	MXXEUXNQ	MnL1TY5pcWKrdHnvckBw\iCDQlygZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDFwMUW5JO69VQ>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
HEK293	NU\4XJY6TnWwY4Tpc44hSXO\|YYm=		MXqxJIg>	MmTjSG1UVw>?	NGPtb5FKdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh\|ryP	MknrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MUK0NVQoRjJzOEGyOFE1RC:jPh?=
HEK293	MljYSpVv[3Srb36gRZN{[Xl?		Mlz3NUBp	NGTzNHBFVVOR	NHrmPXpKdmirYnn0bY9vKG:oIFnSJIF{e2W\|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1?	M{jRUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEGyOFE1Lz5{MUixNlQyPDxxYU6=
Jurkat	NFPK[npHfW6ldHnvckBCe3OjeR?=		Mn\ENUBp	NWCzd21{TE2VTx?=	NFPWPIdKdmirYnn0bY9vKG:oIFzDT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMj63OFEh\|ryP	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThzMkSxOEc,OjF6MUK0NVQ9N2F-
KARPAS299	MkPVT4lv[XOnIFHzd4F6		NGXQWpMyKGh?	MWfEUXNQ	NXjleYJrUW6qaXLpeIlwdiCxZjDBUGsh[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFIh\|ryP	NVnTS\|ZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVI1OTRpPkKxPFEzPDF2PD;hQi=>
PAE	Mk\oSpVv[3Srb36gRZN{[Xl?		M4LCelEhcA>?	MoTPSG1UVw>?	NEnQVJhKdmirYnn0bY9vKG:oIGTST2Ih[XO\|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuN\|k6KM7:TR?=	NIKxPXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
PAE	MnfnSpVv[3Srb36gRZN{[Xl?		MWexJIg>	MXzEUXNQ	MXzJcohq[mm2aX;uJI9nKFSUS1GgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:\|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNUig{txO	NGX2NGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixNlQyPCd-MkG4NVI1OTR:L3G+
BAF3	MXfGeY5kfGmxbjDBd5NigQ>?		M4\EPFIuOyCm	MVrEUXNQ	NF6yTWdKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDpcpN2dGmwIILlZ4VxfG:{IHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOS54NEOg{txO	NWL4bmdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
BAF3	NFixVWxHfW6ldHnvckBCe3OjeR?=		MWOyMVMh\A>?	NGnjNVlFVVOR	NWL2b4pOUW6qaXLpeIlwdiCxZjDOVG0u\nW\|ZXSgRWxMKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhOiC2bzCzJIRigXNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6KHerdHigTWM2OCCxZjCwMlE2ODhizszN	NHHzT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
BAF3	NUC4W2N6TnWwY4Tpc44hSXO\|YYm=		M1HhW\|IuOyCm	NUL4W2dHTE2VTx?=	MknQR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{Bi\nSncjCyJJRwKDNiZHH5d{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmge4l1cCCLQ{WwJI9nKDNwNEe5JO69VQ>?	NUjveIMyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OFIzPTJpPkKzO\|QzOjV{PD;hQi=>
KARPAS299	MV7DfZRwfG:6aXOgRZN{[Xl?		MWSyMVMh\A>?	M4fR[2ROW09?	MkXGTWM2OD1yLkC2OFIh\|ryP	NIPFSpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0NlI2Oid-MkO3OFIzPTJ:L3G+
EBC1	M{W5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVq3NkBp	NFHPc\|NFVVOR	MUDJR\|UxRTBwMEKzJO69VQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
HCT116	NFzFbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHnO\|IhcA>?	NX7jV5R4TE2VTx?=	M1jGcmlEPTB;MUSuPFIh\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
MCF7	NVPMU5F7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NIL1PIs4OiCq	NEXFRpdFVVOR	M2L6[WlEPTB;OT61PEDPxE1?	MmjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
MDA-MB-231	MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIfzXmk4OiCq	NHy2XGJFVVOR	MU\JR\|UxRTFyLkig{txO	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
MKN45	NIn5OoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWrzTGF5PzJiaB?=	M{e1NmROW09?	NG\6W2VKSzVyPUCuNFE{KM7:TR?=	MoCzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
NCI-H441	M3[5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWS3NkBp	NWXTT2dETE2VTx?=	NHnCbHNKSzVyPUG3MlI2KM7:TR?=	NHLDN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
NCI-H661	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkDNO\|IhcA>?	MomwSG1UVw>?	MVjJR\|UxRTFzLkS3JO69VQ>?	NYS4fFFFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
SK-MEL-28	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmnPO\|IhcA>?	M1zhPGROW09?	NVnqVoR{UUN3ME2xNE46PyEQvF2=	Ml\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
SKOV3	M2\GWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mnr0O\|IhcA>?	NWX1OnR3TE2VTx?=	MYjJR\|UxRTF{Lki1JO69VQ>?	NYnRUJhZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5PVM{OjhpPkKzPVk{OzJ6PD;hQi=>
SNU5	NX;ZUIpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mnn3O\|IhcA>?	M4DTNWROW09?	MXXJR\|UxRTBwMEG2JO69VQ>?	Mn25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
Antiproliferative assay	M{SwfmVDSzF?		M1jJ[\|czKGi{cx?=		NGXadGRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR\|Eh[2WubIOg[ZhxemW\|c3nu[{BmdGW4YYTl[EBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[nIHOtUYV1KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjB3MzFOwG0v	NEnYN2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2N\|UzQSd-MkK4OlM2Ojl:L3G+
Function assay	NIj2S45MSVKSQWOyPVk>		MYi3NkBpenN?		NUD4bIMxUW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gT2FTWEGVMkm5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiR3zvJIF{e2G7LDDJR\|UxKD1iMD6wOlIh\|ryPLh?=	M2rCSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	MmDGUmlJNTOWMx?=		M{PTUFEhcHJ?		NXHlUo5uUW6qaXLpeIlwdiCxZjDoeY1idiC5aXzkJJR6eGViRV3MOE1nfXOnZDDBUGsh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJIFnfGW{IEGgbJIh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUAxNjB6IN88UU4>	NFfyd4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NYLlfJd6VkOLLVizNVIz		M2jXbFczKGi{cx?=		MYjJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldkBIdG9iYYPzZZktKEmFNUCgQUAxNjFyODFOwG0v	NHXUTGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	NVrPeXZnVkOLLViyNlI5		M4H3cFczKGi{cx?=		MoTpTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC5zMUig{txONg>?	MlTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	MYXOTWguO1R\|		NULBS2hCOSCqch?=		MmC0TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkG2OUDPxE1w	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	NX7nOWg3VkmKLUPUNy=>		MkHENUBpeg>?		MnL1TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkS3PEDPxE1w	M1SwelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	NGPpSGlPUUhvM2Sz		MlrLNUBpeg>?		M3HRc2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugS\|EzPjmDIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD62NFUh\|ryPLh?=	NX;JOldkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	NGC1RZJPS0lvSEOxNlI>		NVTEV3l5PzJiaILz		MUTJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDHNVI3QUFibYX0ZY51KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwJF0hOC54MkOg{txONg>?	NFHW[XY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESzNlkxQSd-MkS0N\|I6ODl:L3G+
Function assay	MoTXUmlJNTOWMx?=		NEH4[moyKGi{		NFfxNnhKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJHMyOjB4WTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuOlI3KM7:TT6=	M4PHbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEOyPVA6Lz5{NESzNlkxQTxxYU6=
Function assay	MUDOR2kuUDNzMkK=		Mn7OO\|IhcHK\|		NXe2Z481UW6qaXLpeIlwdiCxZjDBUGsu\nW\|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHjhdoJwemmwZzDBUGshVDFzOU\NJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{IFfsc{Bie3OjeTygTWM2OCB;IECuPFM5KM7:TT6=	Ml\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{K5NFkoRjJ2NEOyPVA6RC:jPh?=
Function assay	M4C5Z25KUC1\|VEO=		Ml3YNUBpeg>?		MoSwTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE6Pk1ibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLki0N{DPxE1w	NUfH[HkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	MYHOTWguO1R\|		NHXJfW0yKGi{		NGDp[21KdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTV{UjDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IEGuNFI3KM7:TT6=	NXjLdnU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|I6ODlpPkK0OFMzQTB7PD;hQi=>
Function assay	MYrOTWguO1R\|		NYHCSmFbOSCqch?=		NVrHTJJQUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{AyOTVzVHnud{BufXSjboSg[ZhxemW\|c3XkJIlvKG2xdYPlJG5KUC1\|VEOgZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXygZYZ1\XJiMTDodkBjgSC\|YX7ke4lkcCCHTFnTRUwhUUN3MDC9JFMvODN7IN88UU4>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|MkmwPUc,OjR2M{K5NFk9N2F-
Function assay	MYDCRWY{		M4S0b\|czKGi{cx?=		M3zieWlvcGmkaYTpc44hd2ZiTmDNM2FNUyBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMEWxJO69VS5?	M3iyWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NE[4OlMzLz5{NES2PFY{OjxxYU6=
Function assay	NXO0cFFvSkGIMx?=		MmrhO\|IhcHK\|		M2\MSGlvcGmkaYTpc44hd2ZiTmDNM2FNUyBqdX7rco94diCxcnnnbY4qKHS{YX7z[oVkfGWmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwMEWxJO69VS5?	MmnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2Nki2N\|IoRjJ2NE[4OlMzRC:jPh?=
Function assay	NETpfJlDSUZ\|		MnHKO\|IhcHK\|		MVzJcohq[mm2aX;uJI9nKE6STT;BUGshVDFzOU\NJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIITyZY5{\mWldHXkJIlvKG2xdYPlJGJCTjNiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgX\|NJZS22aIntbYRqdmViaX7jc5Jxd3KjdHnvckBie3OjeTygTWM2OCB;IECuNlYh\|ryPLh?=	NHrXfmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES2PFY{Oid-MkS0Olg3OzJ:L3G+
Cytotoxicity assay	NFzR[W9DSUZ\|		NHLISGQ4OiCqcoO=		NYjmSnVPS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliW{PIYU11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDhd5NigSxiSVO1NEA:KDBwOUig{txONg>?	NVTiWHp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0Olg3OzJpPkK0OFY5PjN{PD;hQi=>
Antiproliferative assay	MWrOTWgwO1R\|		MWm3NkBpenN?		MknVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDjdol7d3SrbnniMZJme2m\|dHHueEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyC4YYLpZY51KDFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEm1OEDPxE1w	NX\CR3RZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFU1PjVpPkK0O\|g2PDZ3PD;hQi=>
Antiproliferative assay	NYLscHNLW1WSLV2y		MYS3NkBpenN?		Mmm2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVWCtUVIh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVc1KM7:TT6=	M2\mRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{i1OFY2Lz5{NEe4OVQ3PTxxYU6=
Antiproliferative assay	NWfyRWRKVkmKL{PUNy=>		NHvSUJI4OiCqcoO=		NW\2XGF4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBkemm8b4TpcoljNXKnc3nzeIFvfCCvb4Xz[UBPUUhxM2SzJINmdGy\|IHjhdoJwemmwZzDFUWw1NUGOSzD2ZZJq[W62IEGvUFEyQT[PIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC54ME[g{txONg>?	NUPBTWhHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFU1PjVpPkK0O\|g2PDZ3PD;hQi=>
Function assay	Ml3nUmlJNTOWMx?=		M3j0OlEhcHJ?		NUTkPZdKUW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgbJVu[W5iRV3MOE1nfXOnZDDBUGsh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJIFnfGW{IEGgbJIh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUAxNjB6IN88UU4>	NYL6R3lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	MVnOTWguO1R\|		MoLXNUBpeg>?		M3;nd2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugSlEyPzSOIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViTlnIMVNVOyClZXzsd{Bie3Onc4Pl[EBieyCyaH;zdIhwNUGOSzDs[ZZmdCCjZoTldkAyKGi{IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6xOlUh\|ryPLh?=	NUfWN\|BMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	NUPWfFRpVkmKLUPUNy=>		NVHBOog{OSCqch?=		Mo\JTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDDNVE2PllibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkS3PEDPxE1w	M33XV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	NU\K[\|RkVkmKLUPUNy=>		M3P0WFEhcHJ?		MlzSTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDHNVI3QUFibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SCQSVitN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHCqb4PwbI8uSUyNIHzleoVtKGGodHXyJFEhcHJiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLk[wOUDPxE1w	NXX0dZlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	MWXOTWguO1R\|		M3rUZlEhcHJ?		NVzyW\|ZMUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BUOTJyNmmgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlYzPiEQvF2u	NFPMXmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	M4XZfm5KUC1\|VEO=		NEPob\|MyKGi{		NIi2XXdKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHnuJI1wfXOnIF7JTE0{XDNiY3XscJMh[XO\|ZYPz[YQh[XNicHjvd5Bpdy2DTFugcIV3\WxiYX\0[ZIhOSCqcjDifUB{[W6md3njbEBGVEmVQTygTWM2OCB;IECuPFQ{KM7:TT6=	NXjKS4k5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	MlrZUmlJNTOWMx?=		MXyxJIhz		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFyxNVUzWiCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDFwMEK2JO69VS5?	M4\2NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG5NVE3Lz5{NEixPVEyPjxxYU6=
Function assay	NIHaTYdPUUhvM2Sz		M2niXVEhcHJ?		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlAzWiCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKE6LSD2zWFMh[2WubIOgZZN{\XO\|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywh[W[2ZYKgNUBpeiCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDFwMUS4JO69VS5?	NEHvWFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixPVEyPid-MkS4NVkyOTZ:L3G+
Function assay	M2HNTW5KUC1\|VEO=		MlLMNUBpeg>?		M3TWVmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDpckBud3W\|ZTDOTWguO1R\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDoc5NxcG9vQVzLJIxmfmWuIHHmeIVzKDFiaIKgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCzMlA{QSEQvF2u	NXzxcWpURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVkyOTZpPkK0PFE6OTF4PD;hQi=>
Function assay	MXjNT245PDV?		MWGxJIhz		NHzqc4VKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOU056NEWgZ4VtdHNiYX\0[ZIhOSCqcjDifUB4\XO2ZYLuJIJtd3S2aX7nMEBKSzVyIE2gNE4xOiEQvF2u	M{joSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwO\|UxLz5{NEmwNFc2ODxxYU6=
Function assay	M{jrUG1MVjh2NR?=		MnP1PVAhdWmwcx?=		NELKVWVKdmirYnn0bY9vKG:oIHOtUYV1KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBOU056NEWgZ4VtdHNiYX\0[ZIhQTBibXnud{BjgSCVYX7ke4lkcC2HTFnTRUwhUUN3MDC9JFAvODJizszNMi=>	NIm0bHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFc2OCd-MkS5NFA4PTB:L3G+
Function assay	MWDrZZJx[XNiMkm5		NVm0fGhwQTBibXnudy=>		M1:xO2lvcGmkaYTpc44hd2ZiTmDNMYZ2e2WmIFHMT{BxcG:\|cHjvdplt[XSrb36gLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hcHWvYX6gb4FzeGG\|IEK5PUBk\WyuczDh[pRmeiB7MDDtbY5{KGK7IGPhcoR4cWOqLVXMTXNCNCCLQ{WwJF0hOC5zMTFOwG0v	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyMEe1NEc,OjR7MEC3OVA9N2F-
Cytotoxicity assay	M17BcW5EUS2KMUm5Ny=>		M3LUfVQ5KGi{cx?=		M1jMXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm5N{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wOlEh\|ryPLh?=	Mmq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
Cytotoxicity assay	MXTOTWgwO1R\|		MWG0PEBpenN?		M3z3eWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJG5KUC9\|VEOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{[0JO69VS5?	NHTEcGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Cytotoxicity assay	NVP4UHJpSTV2OR?=		M{nLd\|Q5KGi{cx?=		MUfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0MlA5PCEQvF2u	M4rrbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMxLz5{NEmwNFg{ODxxYU6=
Cytotoxicity assay	MYjOR2kuUDF7N{W=		MYq0PEBpenN?		NEXuNY9EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEG5O\|Uh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEeuOVUyKM7:TT6=	NF\RVZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OCd-MkS5NFA5OzB:L3G+
Antiproliferative assay	NEPtV4tGSkNz		NGLYbGU4OiCqcoO=		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHPNSXQu[W2ybHnmbYVlKGi3bXHuJGVDSzFiY3XscJMh[W[2ZYKgO\|IhcHK\|LDDJR\|UxKD1iMD6wNFY6KM7:TT6=	NXXTe2dwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzFpPkK0PVAxQDNzPD;hQi=>
Antiproliferative assay	MUfLRXJRSVN{OUm=		NF\XUFM4OiCqcoO=		NF[yNHVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUy2mZYDlcoRmdnRiaIXtZY4hU0GUUFHTNlk6KGOnbHzzJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMjFOwG0v	NHHlWXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFg{OSd-MkS5NFA5OzF:L3G+
Antitumor assay	M4rQZ2JCTjN?	M{KxWVUxKG2pL3vn	M4W3TFIhf2Wna4O=		M4HONWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BnfXOrb36gdJJwfGWrbjDhcIxw\3KjZoTl[EBqdiCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUxKG2pL3vnMEBxdyCzZDDmc5IhOiC5ZXXrd{Bz\WyjdHn2[UB1dyC4ZXjpZ4xmNXS{ZXH0[YQh[2:wdILvcC=>	NWrmVpQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzFpPkK0PVAxQDNzPD;hQi=>
Antiproliferative assay	Mnr2SWJEOQ>?		M1;3V\|czKGi{cx?=		M2j2[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjB{MTFOwG0v	NYTaVXdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1N\|c2OzBpPkK1OVM4PTNyPD;hQi=>
Antiproliferative assay	MkC1V25WPQ>?		MXi3NkBpenN?		MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOQVUWgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjB2IN88UU4>	M1T6NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC1OVI{Lz5{NkCwOVUzOzxxYU6=
Antiproliferative assay	NH3MU3JGSkNz		M{P3OlczKGi{cx?=		MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEWEQ{GgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4xOjF6IN88UU4>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByNUWyN{c,OjZyMEW1NlM9N2F-
Antiproliferative assay	NVXoc4Q1VUuQNEW=		M2S0flczKGi{cx?=		NU\p[m1USW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNT241PSClZXzsd{Bi\nSncjC3NkBpenNuIFnDOVAhRSByLkCzPFEh\|ryPLh?=	NF7wRVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay	NIC1boJDSUZ\|L2TQVk1O\XR?		MoGxO\|IhcHK\|		Moq3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zM3RRWi2PZYSgZ4VtdHNiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNE4yOjd2IN88UU4>	NIi2UIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOVUzOyd-Mk[wNFU2OjN:L3G+
Antiproliferative assay	MlnXUmNKNUh\|MUKy		MUe3NkBpenN?		MnrpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDBUGsu\GWyZX7k[Y51KGi3bXHuJG5EUS2KM{GyNkBk\WyuczDh[pRmeiB5MjDodpMtKEmFNUCgQUAxNjJ4MUKg{txONg>?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5Nke0PUc,OjZ2N{[3OFk9N2F-
Antiproliferative assay	MYXOR2kuUDNzMkK=		MXy3NkBpenN?		M{fOeGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIFz1cYlv\XOlZX70JGNmdGxiVnnhZoltcXS7IFHzd4F6NCCHQ{WwJF0hOC5yM{Kg{txONg>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	NXj6WHVNSmFxRkO=		Ml;FO\|IhcHK\|		NHXvT\|VKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1NUGOSzCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W\|ZTDCZU9HOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNE4xPTZizszNMi=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	NVXEZXJ3SmFxRkO=		NITpUJA4OiCqcoO=		MV7Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0MWFNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEYT;GN{Bk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6wOVYh\|ryPLh?=	NXjRZW5zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	MV;CZU9HOw>?		M4i5d\|czKGi{cx?=		NGH2NFJKdmirYnn0bY9vKG:oIFXNUFQuSUyNIGOxNlA3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwME[1JO69VS5?	MnPvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Function assay	MnOyRoEwTjN?		MW[3NkBpenN?		NIX6fohKdmirYnn0bY9vKG:oIFXNUFQuSUyNIF[xNVc1VCCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMEixJO69VS5?	NFe0eJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Function assay	NG[xRXlD[S:IMx?=		Mn;VO\|IhcHK\|		NHnLVFFKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFOxNVU3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwMUS0JO69VS5?	M2e4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	NXnkephIW02VLVvDUnI>		NEW2UHI4OiCqcoO=		NIi3eGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPNV{1MS06UIHPlcIx{KGW6cILld5NqdmdiRV3MOE1CVEtiUkGyO\|VSKG23dHHueEBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCOdX3pcoV{[2WwdDDD[YxtKF[rYXLpcIl1gSCDc4PhfUwhTUN3MDC9JFAvOTd7IN88UU4>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	MnuwT4VtdHl?		MojPO\|IhcHK\|		NVG5bVRVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDL[YxtgSClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKEZzMUe0UEBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlIyOSEQvF2u	MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	M2fmd2xCVjV?		NUHN[lR6PzJiaILz		NHfp[WlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzBUlUh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BTOTJ5NWGgcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMD6yN\|Ih\|ryPLh?=	M2nnfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Antiproliferative assay	M4LV[2RHS0l5Nh?=		M1W0[VczKGi{cx?=		M33kTGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRF\DTVc3KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshVDFzNULSJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuNlM{KM7:TT6=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Function assay	NFi4UpFD[S:IMx?=		NIjmbVU4OiCqcoO=		NIj2NnNKdmirYnn0bY9vKG:oIFXNUFQuSUyNIFexNlAzWiCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwM{K4JO69VS5?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4OEK4PUc,OjZ3NkiyPFk9N2F-
Antiproliferative assay	MUnTT{1PNVOK		MofmO\|IhcHK\|		NGnzcWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLMW4uW0hiY3XscJMh\XiycnXzd4lv\yCHTVy0MWFNUyCIMUG3OGwhdXW2YX70JIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE4{PyEQvF2u	NIX0TYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	M17HSmNJVEF{MB?=		M3zF[lczKGi{cx?=		NFLj[IZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPIUGEzOCClZXzsd{BmgHC{ZYPzbY5oKEWPTEStRWxMKFJzMke1VUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8hVHWvaX7ld4NmdnRiQ3XscEBXcWGkaXzpeJkhSXO\|YYmsJGVEPTBiPTCwMlQ{QSEQvF2u	NYP5SWFERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	M3L5TGJiN0Z\|		MnnYO\|IhcHK\|		M3zac2lvcGmkaYTpc44hd2ZiRV3MOE1CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC53MUKg{txONg>?	NFfyUVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	NFW3XFJUUC2VWUXZ		MoLMO\|IhcHK\|		Ml7DRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVSD3TXVV[KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTjFzN{TMJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IECuOVI{KM7:TT6=	M4m2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	M2\aNWJiN0Z\|		MmnaO\|IhcHK\|		M2frXGlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiTEGxPVZOKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC53NEmg{txONg>?	M2H1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NU[4Nlg6Lz5{NkW2PFI5QTxxYU6=
Function assay	NInCfJFD[S:IMx?=		MlTuO\|IhcHK\|		M3O2fmlvcGmkaYTpc44hd2ZiRV3MOE1CVEtiTEGxOVJTKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBD[S:IMzDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCLQ{WwJF0hOC54NEWg{txONg>?	NI\LOlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	MnfoV2suVi2ERTiyLS=>		M{njfFczKGi{cx?=		NVzVTZpESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNUKHKEKpJINmdGy\|IHX4dJJme3Orbnege4lt\CC2eYDlJGVOVDRvQVzLJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKEy3bXnu[ZNk\W62IFPlcIwhXmmjYnnsbZR6KEG\|c3H5MEBGSzVyIE2gNE44OSEQvF2u	NYrGbnBlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Function assay	NXGwd2RISmFxRkO=		M3vNeVczKGi{cx?=		MlLCTY5pcWKrdHnvckBw\iCHTVy0MWFNUyBzMUWxWIlveyCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSmFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwOEW3JO69VS5?	MkPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Cytotoxicity assay	MnHTRmEwTjN?		MXi3NkBpenN?		NVzufWFRS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDBwOUK3JO69VS5?	MnTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	MmK1UGFPOQ>?		Mlf5O\|IhcHK\|		MnSzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCOQV6xJINmdGy\|IHX4dJJme3OrbnegSW1NPC2DTFugSlEyPzSOIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwM{S2JO69VS5?	NFXlRoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW2PFI5QSd-Mk[1OlgzQDl:L3G+
Antiproliferative assay	MWTTT{1PNU[L		NH7Y[FY4OiCqcoO=		NVTPU5RFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1PNU[LIHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJGx2dWmwZYPj[Y51KEOnbHygWoli[mmuaYT5JGF{e2G7LDDFR\|UxKD1iMT60Olkh\|ryPLh?=	NY\1cHhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OlgzQDlpPkK2OVY5Ojh7PD;hQi=>
Antiproliferative assay	MV7TT{1PNUGV		MomzO\|IhcHK\|		M1HkfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1utUk1CWyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDMeY1qdmW\|Y3XueEBE\WyuIG\pZYJqdGm2eTDBd5NigSxiRVO1NEA:KDFwNEezJO69VS5?	MmCyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	MUPESmNKOTF2		MYe3NkBpenN?		MlTjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCGRlPJNVE1KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshTzF{NknBJI12fGGwdDDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BNfW2rbnXzZ4VvfCCFZXzsJHZq[WKrbHn0fUBCe3OjeTygSWM2OCB;IEGuOlE2KM7:TT6=	MmnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3NkiyPFkoRjJ4NU[4Nlg6RC:jPh?=
Antiproliferative assay	M3\UVWVDSzF?		Mn\0O\|IhcHK\|		NFPvRotCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFXCR\|Eh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFE6KM7:TT6=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ7OEWzOkc,OjZ4OUi1N\|Y9N2F-
Cytotoxicity assay	MlHPSWJEOQ>?		MojLO\|IhcHK\|		MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCLQ{WwJF0hOC5yNESg{txONg>?	M1XaZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MEG3OVQ5Lz5{N{CxO\|U1QDxxYU6=
Antiproliferative assay	M4DX[2tCWlCDU{K5PS=>		M37oflczKGi{cx?=		MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDN0OFSz24JIF{e2G7LDDJR\|UxKD1iMD6xNFMh\|ryPLh?=	MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay	MXPTWXAuVTJ?		NHTPcpg4OiCqcoO=		M1voPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XQMW0zKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkGxNkDPxE1w	NY\1UXZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN\|ExPjZpPkK3NVMyODZ4PD;hQi=>
Antiproliferative assay	NVPJTYlrW1VvRFjMNS=>		NEfHZ484OiCqcoO=		MlexRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVVT3ETGwyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkGzOkDPxE1w	Mon5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Antiproliferative assay	MVHOR2kuUDNzMkK=		NXjKS5R{PzJiaILz		NWnGPFY5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDNzMkKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFAvOjFizszNMi=>	MojZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzM{GwOlYoRjJ5MUOxNFY3RC:jPh?=
Function assay	MXTOR2kuUDNzMkK=		M4jjS\|czKGi{cx?=		NY\5UHh3UW6qaXLpeIlwdiCxZjDBUGsh\XiycnXzd4VlKGmwIHj1cYFvKE6FST3IN\|EzOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDTVmIwS0ONLUigZZN{[XluIFnDOVAhRSByLkK2NUDPxE1w	NFTVWpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
Antiproliferative assay	NWP4WIg3VkmKL{PUNy=>		MVW3NkBpenN?		NWnSZpE5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDOTWgwO1R\|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFXNUFQuSUyNIHHmeIVzKDd{IHjyd{BjgSCVUlKvR2NMNThiYYPzZZktKEmFNUCgQUAxNjJ6MzFOwG0v	NFnsXpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVA3Pid-MkexN\|ExPjZ:L3G+
Antiproliferative assay	MlO5UmlJNzOWMx?=		M2Cw[VczKGi{cx?=		MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKE6LSD:zWFMh[2WubIOg[ZhxemW\|c3nu[{BGVUx2LVHMT{BNOTF7NjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQj;DR2suQCCjc4PhfUwhUUN3MDC9JFEvOTZizszNMi=>	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF\|MUC2Okc,OjdzM{GwOlY9N2F-
Antiproliferative assay	NGLnW2FCVEtvcH;zbZRqfmViS1HSVGFUOjl7		NYriZnBXPzJiaILz		NV;RPHl[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBUGsueG:\|aYTpeoUhU0GUUFHTNlk6KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzKDl4IHHxeYVwfXNib37lJJNwdHW2aX;uJINmdGxicILvcIln\XKjdHnvckBie3OjeTygTWM2OCB;IECuN\|Y2KM7:TT6=	NETuT4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G0OFg{OSd-MkexOFQ5OzF:L3G+
Antiproliferative assay	MUjBUGsudmWpYYTpeoUhXTl\|Nx?=		MnGyO\|IhcHK\|		M3XBUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQVzLMY5m\2G2aY\lJHU6OzdiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiOU[gZZF2\W:3czDvcoUhe2:udYTpc44h[2WubDDwdo9tcW[ncnH0bY9vKGG\|c3H5MEBKSzVyIE2gNk4zQDZizszNMi=>	M1ntUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUS0PFMyLz5{N{G0OFg{OTxxYU6=
Cytotoxicity assay	MUDI[ZBIOg>?		NXzzN3VFPzJiaILz		MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55IN88UU4>	M2X2flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{m2PVI6Lz5{N{O5OlkzQTxxYU6=
Cytotoxicity assay	NF3yO4JOUUGSYVPhNi=>		NITLeWc4OiCqcoO=		NITQTVhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOUUGSYVPhNkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gO{4yPiEQvF2u	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OU[5NlkoRjJ5M{m2PVI6RC:jPh?=
Cytotoxicity assay	NUO2U4tWUEOFOEK3		NHrTR3A4OiCqcoO=		NUTvW5duS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOFOEK3JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3MlI2KM7:TT6=	NIDBfmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5OlkzQSd-MkezPVY6Ojl:L3G+
Cytotoxicity assay	NVrKU4pvU0GUUFHTNlk6		M4rB[\|czKGi{cx?=		NID1eJFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSVKSQWOyPVkh[2WubIOgbIFz[m:{aX7nJG5RVS2DTFugZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wOlgh\|ryPLh?=	MlTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{S5NlUoRjJ5NEe0PVI2RC:jPh?=
Cytotoxicity assay	MWXIR2M4QA>?		NHXJXWw4OiCqcoO=		MlT5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNEPzhiY3XscJMhcGG{Yn;ybY5oKFOOQ{O0RVIuWk:VMTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkO0JO69VS5?	MoXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd2N{S5NlUoRjJ5NEe0PVI2RC:jPh?=
Antiproliferative assay	MYPTWU1FUExz		NInMWWw4OiCqcoO=		M4LkTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgRWxMKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBpfW2jbjDTWU1FUExzIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvODl{MzFOwG0v	NGfZbHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVYzOyd-Mke3Olk3OjN:L3G+
Antiproliferative assay	M4T2NG5EUS2KM{GyNi=>		MmXLO\|IhcHK\|		NGHGS4FCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gUmNKNUh\|MUKyJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMUCwPUDPxE1w	MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5Nkm2NlMoRjJ5N{[5OlI{RC:jPh?=
Antiproliferative assay	M2DPVGtCWlCDU{K5PS=>		NIDaR3U4OiCqcoO=		NF3pb49CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGFNUyClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhcHWvYX6gT2FTWEGVMkm5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwMUC0PUDPxE1w	M3X4flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5OlI{Lz5{N{e2PVYzOzxxYU6=
Function assay	Moi3UmlJNzOWMx?=				M2DPfWlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJG5KUC9\|VEOgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5?	NF;iSFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	NX;RdJA{VkmKL{PUNy=>				MVLJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC5yODFOwG0v	M4fyUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	MlPTUmlJNzOWMx?=				NI\iRYpKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDGNVE4PExibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjF4NTFOwG0v	MlLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	MmTsUmlJNzOWMx?=				NUDUW2t4UW6qaXLpeIlwdiCxZjD3bYxlKHS7cHWgSW1NPC:DTFugSlEyPzSOIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDOTWgwO1R\|IHPlcIx{NCCLQ{WwJF0hOC5zNkWg{txONg>?	NID4bVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MVXOTWgwO1R\|				M13Tb2lvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFOxNVU3YSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvPDd6IN88UU4>	NGHSN4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	MXzOTWgwO1R\|				Mk\3TY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiQ{GxOVZ[KG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE41PzhizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	NELkeJVPUUhxM2Sz				NHvzZXhKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVI3QUFibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZyNTFOwG0v	M3nYS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	NHvyb3NPUUhxM2Sz				Ml3aTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiR{GyOllCKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCQSVivN3Q{KGOnbHzzMEBKSzVyIE2gNE43ODVizszNMi=>	NETGO3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESzNVM1OCd-Mki0N\|E{PDB:L3G+
Function assay	NHPkV3RPUUhxM2Sz				NGjsPYdKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDTNVIxPllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZ{NjFOwG0v	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	MUfOTWgwO1R\|				NFPlem1KdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDTNVIxPllibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjZ{NjFOwG0v	M4mwcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	M{DISm5KUC9\|VEO=				NGTTc5FKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDMNVE6Pk1ibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAxNjh2MzFOwG0v	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{GzOFAoRjJ6NEOxN\|QxRC:jPh?=
Function assay	NGnCW\|RPUUhxM2Sz				M3LDfmlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFXNUFQwSUyNIFyxNVk3VSCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFAvQDR\|IN88UU4>	NX71ZXgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	NWr5TYZTVkmKL{PUNy=>				MXvJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCOMUG1NnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCxMlAzPiEQvF2u	M4LKPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOxN\|QxLz5{OESzNVM1ODxxYU6=
Function assay	NFzie\|dPUUhxM2Sz				NGjtV\|JKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDMNVE2OlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjB{NjFOwG0v	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	Mn3nUmlJNzOWMx?=				NHvNTIZKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDFUWw1N0GOSzDHNVIxOlJibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUAyNjF2ODFOwG0v	NUO3WZQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Function assay	MXfOTWgwO1R\|				MVfJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyCJMUKwNnIhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKE6LSD:zWFMh[2WubIOsJGlEPTBiPTCxMlE1QCEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	MlrXUmlJNzOWMx?=				MW\Jcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHTVy0M2FNUyBzMUWxWIlveyCvdYThcpQhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iTlnIM\|NVOyClZXzsd{whUUN3MDC9JFMvODN7IN88UU4>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO0NEc,Ojh2M{GzOFA9N2F-
Function assay	Mn\2UmlJNzOWMx?=				MmPZTY5pcWKrdHnvckBw\iC5aXzkJJR6eGViRV3MOE9CVEtiMUG1NXRqdnNibYX0ZY51KCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIF7JTE8{XDNiY3XscJMtKEmFNUCgQUA{NjB\|OTFOwG0v	NXf2enY3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0N\|E{PDBpPkK4OFMyOzRyPD;hQi=>
Cytotoxicity assay	M3LaZ2VDSzF?		MmTlO\|IhcHK\|		NGjmXYZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBGSkNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygRYN1cX[rdImgQUAxNjBzMzFOwG0v	M{LvOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Cytotoxicity assay	NGe5eHdOU052NR?=		MUS3NkBpenN?		M2XvbWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1MVjR3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDd{IHjyd{BjgSCFZXzsJHRqfGW{LVfsc{Bie3OjeTygRYN1cX[rdImgQUAxNjB{MjFOwG0v	M1ez[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{W1OlM2Lz5{OEe1OVY{PTxxYU6=
Cytotoxicity assay	MkLiVGM{		NYfjPWppPzJiaILz		NHnMZlBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KEOnbHygWIl1\XJvR3zvJIF{e2G7LDDBZ5Rqfmm2eTC9JFIvOjR2IN88UU4>	NVXyXGFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OVU3OzVpPkK4O\|U2PjN3PD;hQi=>
Function assay	NVrYXo8{SkGIMx?=		NEDld3E4OiCqcoO=		MlnnTY5pcWKrdHnvckBw\iCHTVy0MYZ2e2WmIFHMT{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODByMzFOwG0v	NVfqNFduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Function assay	MknkRmFHOw>?		NYLi[nk2PzJiaILz		NH;4WlRKdmirYnn0bY9vKG:oIF7QUU1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	NHm1N3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Function assay	M4\LPGJCTjN?		MXm3NkBpenN?		NHfqWWdKdmirYnn0bY9vKG:oIGTFUE1nfXOnZDDBUGshMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5ibX;1d4UhSkGIMzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIDyc4xq\mW{YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	M1HMOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWwPVIzLz5{OEi1NFkzOjxxYU6=
Antiproliferative assay	NHP5TlRPS0lvSEOxNlI>		NFHEN3U4OiCqcoO=		M3rTbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCHTVy0MYZ2e2WmIFHMT{B3[XKrYX6xJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOzdizszNMi=>	MkfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUC5NlIoRjJ6OEWwPVIzRC:jPh?=
Antiproliferative assay	M1LzNm5EUS2KMkKyPC=>		NH3SbHU4OiCqcoO=		MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INlIzQCClZXzsd{Bp[XKkb4LpcochTU2OND3meZNm\CCDTFugeoFzcWGwMzDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFc{KM7:TT6=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay	MWPCRWY{		M3vjSVczKGi{cx?=		M3fR[mlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFHMT{BEOTF3NmmgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6xOUDPxE1w	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay	NGHIU3JDSUZ\|		NXjDUph1PzJiaILz		NXTJZmlsUW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBCVEtiRkGxO\|RNKG23dHHueEApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCvb4Xz[UBDSUZ\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxicILvcIln\XKjdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvOzJizszNMi=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay	NEmyTG1DSUZ\|		MmjmO\|IhcHK\|		M{e2dGlvcGmkaYTpc44hd2ZiVFXMMYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBSlMh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD60N{DPxE1w	NIPFW4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay	M{LySmNJVA>?		NVzt[IdjPzJiaILz		NGrZUFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGNJVCClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvPDVizszNMi=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Function assay	NXnj[opUSkGIMx?=		NFrRfoQ4OiCqcoO=		MXnJcohq[mm2aX;uJI9nKFSHTD3meZNm\CCDTFugUFEyQT[PIH31eIFvfCBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDtc5V{\SCEQV[zJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwNUmg{txONg>?	NG[4cmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1NFkzOid-Mki4OVA6OjJ:L3G+
Antiproliferative assay	M1r3O2JCTjN?		Mlz5O\|IhcHK\|		M2jPVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IEGuNUDPxE1w	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3MEmyNkc,Ojh6NUC5NlI9N2F-
Antiproliferative assay	MV\DTG8>		M2LHSVczKGi{cx?=		MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFPIU{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IEOuNkDPxE1w	NYm0[4RSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVA6OjJpPkK4PFUxQTJ{PD;hQi=>
Antiproliferative assay	NW\LfZl{VkOLLViyNlI5		NWTH[Y51PzJiaILz		M1y4dmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAzNjVizszNMi=>	NIHOSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC5NVQzPSd-MkmwPVE1OjV:L3G+
Antiproliferative assay	NFq3TFRJOjJ{OD;DVi=>		MUO3NkBpenN?		M17xUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSEKyNlgwS1JiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFExKM7:TT6=	MkHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlyOUG0NlUoRjJ7MEmxOFI2RC:jPh?=
Function assay	MlvvTFIzOjh?	NUnqXHBOOC53IIXN	NWXEc3BHOyCqcoO=		NHzreYdKdmirYnn0bY9vKG:oIFHMT{BqdiCqdX3hckBJOjJ{ODDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IECuOUB2VSCjZoTldkA{KGi{czDifUBY\XO2ZYLuJIJtd3RibXX0bI9l	NUjwcJdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Function assay	NGfoOohD[S:IMx?=	MUGwMlEhfG9iMTD1US=>	NEniTpY4OiCqcoO=		NY\Q[nJXUW6qaXLpeIlwdiCxZjDoeY1idiC5aXzkJJR6eGViRV3MOEBnfXOnZDDBUGsh\XiycnXzd4VlKGmwIH3veZNmKEKjL1[zJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygdJJwdGmoZYLheIlwdiCjdDCwMlEhfG9iMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFczKGi{czDmc4xtd3enZDDifUBu\XSqeXytN2gufGi7bXnkbY5mKGmwY3;ydI9z[XSrb36gcYVie3W{ZXSgZYZ1\XJiODDodpMh[nliZnnseIVzKHOlaX70bYxt[XSrb36gZ492dnSn	NUPXRY5MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwPVE1OjVpPkK5NFkyPDJ3PD;hQi=>
Antiproliferative assay	NFL6UXdMSVKSQWOyPVk>		NHy1eW44OiCqcoO=		MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuDUmDBV\|I6QSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xQDdizszNMi=>	NXe1RZF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5ODlpPkK5NVc1QDB7PD;hQi=>
Antiproliferative assay	M3fKOGhESzd6		M1u2cFczKGi{cx?=		NY\TOWIzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR2M4QCClZXzsd{Bp[XKkb4LpcochW0yFM{TBNk1TV1NzIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkG3JO69VS5?	NELFWWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgxQSd-MkmxO\|Q5ODl:L3G+
Antiproliferative assay	MVrOR2kuUDJ{Mki=		M1TKWVczKGi{cx?=		M1;X[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{NDFOwG0v	NWTYeWU5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxO\|Q5ODlpPkK5NVc1QDB7PD;hQi=>
Antiproliferative assay	MmG5UmNKNUh\|MUKy		NFTwVlc1QCCqcoO=		M3u5U2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjhizszNMi=>	NHLncos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3OFgyPCd-MkmxO\|Q5OTR:L3G+
Antiproliferative assay	NY\hT297UEOFN{i=		NXrWToVXPDhiaILz		M1iw[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPDO\|gh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKg{txONg>?	Mn\mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{S4NVQoRjJ7MUe0PFE1RC:jPh?=
Antiproliferative assay	NUDXR4FqTUKFMR?=		MVO3NkBpenN?		M2XIcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSxiSVO1NEA:KDBwMEGzJO69VS5?	M2LnO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	NIHaN3lOU052NR?=		MYO3NkBpenN?		NHXlU21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3LUlQ2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7LDDJR\|UxKD1iMD6wNlIh\|ryPLh?=	MnSzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay	MmLhUWNHPw>?		MkjpO\|IhcHK\|		MlnORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCDbHHtZZJjdHWnIHHzd4F6KHKnbHH0bZZmKHSxIHPvcpRzd2xuIFnDOVAhRSByLkC0OUDPxE1w	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	M1;m[mE2PDl?		NInTd3E4OiCqcoO=		M{fGS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliQXzhcYFz[my3ZTDhd5NigSC{ZXzheIl3\SC2bzDjc451em:uLDDJR\|UxKD1iMD6xN\|Q{KM7:TT6=	M1rEV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	NFL1XFJJS1RzMU[=		M1S4UlczKGi{cx?=		NVflSZBmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcnLseYUh[XO\|YYmgdoVt[XSrdnWgeI8h[2:wdILvcEwhUUN3MDC9JFAvOjV\|NjFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJyMkSxNEc,Ojl{MEK0NVA9N2F-
Antiproliferative assay	NX\SeXJNW0eFN{mwNS=>		MVi3NkBpenN?		NYr1cnBVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTS2M4QTBzIHPlcIx{KGGodHXyJFczKGi{czDifUBCdGGvYYLicJVmKGG\|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4wtKEmFNUCgQUAxNjN{MUOg{txONg>?	MkXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{MEK0NVAoRjJ7MkCyOFExRC:jPh?=
Antiproliferative assay	MnXTUmNKNUh2NkC=		MlP1O\|IhcHK\|		MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDBcIFu[XKkbIXlJIF{e2G7LDDJR\|UxKD1iMj6yOFQh\|ryPLh?=	M{TsdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MkCyOFExLz5{OUKwNlQyODxxYU6=
Antiproliferative assay	NFvxVWFEV0yRMkC1		MV23NkBpenN?		NH;zOmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFPPUG8zODViY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGFt[W2jcnLseYUh[XO\|YYmsJGlEPTBiPTCyMlQ1QSEQvF2u	NGfnW\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	NHzT[YpRSzN?		MljTO\|IhcHK\|		NU[0dndRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFHsZY1iemKudXWgZZN{[XluIFnDOVAhRSB7Lke4O{DPxE1w	NIrwWHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUKwNlQyOCd-MkmyNFI1OTB:L3G+
Antiproliferative assay	MkDoRmFHOw>?		MV:3NkBpenN?		NYTVb5F3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BETDd2LWLPV\|Eh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4xPDh4IN88UU4>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	MlLzRmFHOw>?		M{DDR\|czKGi{cx?=		NVX6ZmNESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlA2PzVizszNMi=>	NHL5b4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	M{jVOnNWNUSKTEG=		NYizZ4dwPzJiaILz		M2HOO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2WtSGhNOSClZXzsd{Bp[XKkb4LpcochVlCPLVHMT{Bi\nSncjC3NkBpenNiYomgV3JDKG:{IFPDT\|gh[XO\|YYmsJGlEPTBiPTCwMlE2PSEQvF2u	NGPUfGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	M1HKfGtCWlCDU{K5PS=>		NFTpWHU4OiCqcoO=		M2DUUGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1HSVGFUOjl7IHPlcIx{KGijcnLvdolv\yCQUF2tRWxMKGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvOTd4IN88UU4>	NG\kNJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
Antiproliferative assay	M3jG[m5EUS2KM{GyNi=>		MUG3NkBpenN?		MkXrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFMyOjJiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCxcjDDR2s5KGG\|c3H5MEBKSzVyIE2gNE4{ODNizszNMi=>	Mnq5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{OEi5OFAoRjJ7Mki4PVQxRC:jPh?=
Antiproliferative assay	NE\yNlFDSUZ\|		NWq5TIRNPzJiaILz		NXu5RWpiSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BGVUx2LVHMT{BNOTF7Nl2gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCVUlKgc5IhS0ONODDhd5NigSxiSVO1NEA:KDBwM{Sg{txONg>?	NWTPSGdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	NHvQ[FZDSUZ\|		NHrzXXE4OiCqcoO=		NHHlcWRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGVOVDRvQVzLJGcyOjB{UjDteZRidnRiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC53NkSg{txONg>?	M2nLRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7Mki4PVQxLz5{OUK4PFk1ODxxYU6=
Antiproliferative assay	NV7ocJdISkGIMx?=		NHfPbpk4OiCqcoO=		MnW1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDDSFc1NVKRU{GgS\|IxOzKUIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIH;yJGNEUzhiYYPzZZktKEmFNUCgQUAxNjV7NDFOwG0v	NVjiTG5yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmyPFg6PDBpPkK5Nlg5QTRyPD;hQi=>
Antiproliferative assay	M3jpPGJCTjN?		NVizbJp4PzJiaILz		MnXvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDJUFMue3SrbYXsZZRm\CCvb4Xz[UBDSUZ\|IHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJib4KgR2NMQCCjc4PhfUwhUUN3MDC9JFAvPjR2IN88UU4>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ6OEm0NEc,Ojl{OEi5OFA9N2F-
Antiproliferative assay	MWHIR2M4QA>?		NHvPOms4OiCqcoO=		NHPtUVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIhiemKxcnnu[{BUVEN\|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KFOUQjDvdkBES0t6IHHzd4F6NCCLQ{WwJF0hOC56OEmg{txONg>?	NGfveoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK4PFk1OCd-MkmyPFg6PDB:L3G+
qHTS assay	NV7oeYRWXEN\|Mh?=				NXfRTWE1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGTDN\|Ih[2WubIO=	NYXaSYU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NXW5[4VGSTZ5Mx?=				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	M2nwRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NGLWdIJU[W:\|LUK=				Mmr6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?=	NXLuRVBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M2jtTHJF				M{PuPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>?	NUTlSpdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MVTTT{1PNVOK				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NXnrfWtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M3:5UmJVNTF{				NI\GNJdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	M1ftdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NGHxTHROTyB4MzCoOk1VTyCUKR?=				NXTFXJRReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	NVzhVJVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M4H5U25DOTZ2Mx?=				MoXGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MmfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NUfOTW9HV0iVLUWw				NInEV\|dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M3LNb2xCVi13				NVvRblZueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	MmHLUmIuTUKlMR?=				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	M4Xz[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NF3ZcG5UUy2QLWPI				M3jIbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	NX3OcIRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M4XpR3JpPDF?				NHW5RW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	NHfQcIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	M4PRbWE3PzN?				M1TqWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	NWHwWIpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NXzMUJVOWmh\|MB?=				NF6yc2tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
qHTS assay	M2n3XWJVNTN5				NEP3NGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1\|NzDj[Yxtew>?	MmOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	M2TV[W1IKDZ\|IDi2MXRIKFJr				NFf6UodyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NVzOeGE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	MmDwVog{OA>?				MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	MkfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	MmPXU2hUNTVy				MlfWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{	NV7Hc\|NKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	M{OybXNLNUeETUK=				NV3McnBMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NIC1S2xUUy2QLV3D				Moi1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	Mn\VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NWLmNoZiVkJvRVLjNS=>				MkC5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MkPkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
qHTS assay	NIDBfplNSU5vNR?=				NEPXdmhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	NHfXWpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
qHTS assay	NXrkUmpCWmhzOB?=				M{nreZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	M{G3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NFuxO3RPSjF4NEO=				NGDXSIRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN?	NXHiSIFkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
qHTS assay	NUjQO3JOW0tvTj3NRy=>				NHzhXm1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	M1TPU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	M4\HfXREOzJ?				NEi4XGRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	M3zGR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	NWfXZ2RNWmhzOB?=				Mn7TdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	M3yxPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
qHTS assay	MmLiV4Fwey1{				NIDCSGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Antiproliferative assay	NX\OT2RlTUKFMR?=		MnvmO\|IhcHK\|		NVnjWoFXSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtKFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFAvODN7IN88UU4>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZyMkCzOkc,Ojl4MEKwN\|Y9N2F-
Function assay	NEjnUIlJezV5OGS=	NIXyV4kyODBibl2=	MYizNEBucW6\|		M3nvU2lvcGmkaYTpc44hd2ZiaHXwd4lvNW2nZHnheIVlKGOxbo\ldpNqd25ib3[gVJJwNUiJRjDpcpRwKGGldHn2[UBnd3KvIHnuJIh2dWGwIFjzOVc5XCClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDNSXQheGixc4Doc5J6dGG2aX;uJIF1KDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhemWlb33ibY5idnRiaIXtZY4heHKxLVjHSkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCzNEBucW6\|IHL5JIludXWwb3Lsc5QhdQ>?	M2qx[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{CxPVYzLz5{OUewNVk3OjxxYU6=
Function assay	NHT3dJBJS0NzOUO3	MYexNFAhdk1?	NH7aPGQ{OCCvaX7z		MoTTTY5pcWKrdHnvckBw\iCqZYDzbY4udWWmaXH0[YQh[2:wdnXyd4lwdiCxZjDQdo8uUEeIIHnueI8h[WO2aY\lJIZwem1iaX6gbJVu[W5iSFPDNVk{PyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDNSXQheGixc4Doc5J6dGG2aX;uJIF1KDFyMDDuUUBxemWrbnP1ZoF1\WRiZn;yJFMxKG2rboOg[o9tdG:5ZXSgZpkhemWlb33ibY5idnRiaIXtZY4heHKxLVjHSkBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCzNEBucW6\|IHL5JIludXWwb3Lsc5Q>	M3e2RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{CxPVYzLz5{OUewNVk3OjxxYU6=
Antiproliferative assay	NXPJe2RlVkOLLViyNlI5		MUW3NkBpenN?		M2OzWmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWgzOjJ6IHPlcIx{KGijcnLvdolv\yCHTVy0MWFNUyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>?	MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
Antiproliferative assay	M37JXWhESzd6		M1\YRVczKGi{cx?=		NG\6cJRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR\|c5KGOnbHzzJIhiemKxcnnu[{BUVEN\|NFGyMXJQWzFiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUeg{txONg>?	NX;tcW5WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNlMyOjBpPkOwNlI{OTJyPD;hQi=>
Antiproliferative assay	NYLP[2pCU0GUUFHTNlk6		NWG3bFJXPzJiaILz		NYfST3ZzSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN{OUmgZ4VtdHNiaHHyZo9zcW6pIF7QUU1CVEtiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMkSg{txONg>?	MmG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MkOxNlAoRjNyMkKzNVIxRC:jPh?=
NB1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHVVpptUUN3ME25NU46QCCwTR?=	M1m4VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-SNU-5	NWDBSoxFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3Ls[2lEPTB;MUC1Mlc2KG6P	NH3Pd\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
SR	NXTGUWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\0TWlEPTB;MUK2MlMyKG6P	M{n4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SF539	Mmm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofPTWM2OD1{MESuNlQhdk1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SU-DHL-1	Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLrTWM2OD1\|M{[uPFIhdk1?	MljZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
SCC-3	MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\YTWM2OD1\|NU[uO\|Yhdk1?	MkT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
DEL	NEnBbpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTN4OT65JI5O	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CTV-1	NFzZUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTV7Nj60PEBvVQ>?	NUXmfodDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
EM-2	NWDnPWlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzKTWM2OD14MEGuN\|Qhdk1?	NFTMcGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
MHH-CALL-2	NEe2O5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HDOGlEPTB;NkiyMlU4KG6P	MmfRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KM12	NGnnV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTtTWM2OD15ME[uPUBvVQ>?	NFjaWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KINGS-1	NF;lfJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTd2OT63OUBvVQ>?	M{O1VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MEG-01	Mn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;OZXhKSzVyPUi1O{43PiCwTR?=	NHPQ[3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
BV-173	M1TUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nMW2lEPTB;MT6wOVk6PyEQvF2=	MnfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
LAMA-84	NEHjWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTFwM{iyPFIh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KARPAS-299	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHBTWM2OD1zLkSwPFYyKM7:TR?=	M{DjOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
K-562	M3fheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTFwN{KyOlkh\|ryP	NV;0PINmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
SK-LMS-1	M3mw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[zTWM2OD1zLke2PFY4KM7:TR?=	NXjJdZBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MOLT-16	M3OzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX2XoFKSzVyPUGuPVU2PzVizszN	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CMK	MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLzTWM2OD1zLkm2NVU6KM7:TR?=	M3TaflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ST486	M2K5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HyTmlEPTB;Mj60N\|A4OyEQvF2=	NXr2TJg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CI-1	MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfOXoR1UUN3ME2yMlQ6PjV7IN88US=>	M1LvZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KP-N-RT-BM-1	Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3TuemlEPTB;Mj63NFEzOiEQvF2=	NE\ITZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
ALL-PO	M2W1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7acIxKSzVyPUOuNVgzODdizszN	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
KS-1	MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HHc2lEPTB;Mz6yNVIzPSEQvF2=	M1LmRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
Becker	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTRwMkO5N{DPxE1?	NULTV251RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
GDM-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTRwMkS2NVch\|ryP	M3LnTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
BC-1	NXXNb5VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmGzTWM2OD12LkS5Nlc4KM7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NB14	NYjveJQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTRwOEO1NlQh\|ryP	MnPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NOS-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXm0UmRHUUN3ME21MlM{QDd2IN88US=>	NUS5dYpTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MZ1-PC	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDNVmFKSzVyPUWuPFIyPTFizszN	NYf2SJRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A498	M3\Od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3L4UmlEPTB;Nj6wPFQ4OyEQvF2=	M4HOe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
EW-16	NYDQZmMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHro[YVKSzVyPU[uN\|c4PzNizszN	NXLEWYJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NALM-6	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjYVGRKSzVyPU[uOlg{QDdizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
EB-3	M3rQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TBU2lEPTB;Nz6wO\|I{OyEQvF2=	Mm\JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
697	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33rO2lEPTB;OT6yOFMzQSEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	NIrqbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTnbpdvUUN3ME25MlU6QDR{IN88US=>	NH\ReWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KNS-81-FD	M1\uXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDBOGVmUUN3ME25MlY6PjV\|IN88US=>	M4DtblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HUTU-80	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDMUHNKSzVyPUmuO\|Q3PDJizszN	NYrqbHgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
LS-411N	M3HnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nKN2lEPTB;MUCuNFU3PyEQvF2=	NHHoUlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
RPMI-8402	MmLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLyflRKSzVyPUGwMlEyPiEQvF2=	NVrDTG44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
KU812	NIHIXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXS5[mxyUUN3ME2xNE4zQTlzIN88US=>	NG[0ToI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
EW-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XlcGlEPTB;MUCuOFQzPSEQvF2=	M1HwZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
HC-1	M1LYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUj3VFRHUUN3ME2xNE41QDR2IN88US=>	NWPOVoZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NB69	M3eyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTCdI1nUUN3ME2xNE42ODR\|IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MFH-ino	NG[4XWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFyLkizNFMh\|ryP	MmHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CCRF-CEM	NVrCOm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPLTWM2OD1zMT61PVch\|ryP	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-N-DZ	NGW2VHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTTZ3VKSzVyPUGyMlA1OzZizszN	NVjsPY1DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-H720	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13YOWlEPTB;MUKuNVcxPSEQvF2=	NYq4R\|VORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HCC1187	MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHQTWM2OD1zMj6yNFQyKM7:TR?=	NGG5XpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
IST-SL2	NGrteXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXTTWM2OD1zMj60PFczKM7:TR?=	M{[0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
KE-37	NVi2V\|lYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn6WHRmUUN3ME2xNk44QTZ4IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
HCC1599	NX;lUnp6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH6yc2xKSzVyPUGyMlkxPjlizszN	M2XYPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
A4-Fuk	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX35ZmR4UUN3ME2xNk46PTh4IN88US=>	M13xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NKM-1	NWn5TlQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnPVm1KSzVyPUGzMlI6OjVizszN	NIHyeIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
BE-13	MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLBN3FKSzVyPUGzMlc6QDlizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
MV-4-11	NIX3TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3ldGFKSzVyPUG0MlA{OjRizszN	MlPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
OPM-2	MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDnTWM2OD1zND60NFg2KM7:TR?=	MkL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KARPAS-422	M3\hOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTF2LkWxNlYh\|ryP	NXO1VI1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
RPMI-8226	MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTF2Lki5NVUh\|ryP	NHLlXoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
KARPAS-45	M2XXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTF3Lke3NVYh\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-PN-DW	MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;HR3FKSzVyPUG1Mlg3OzFizszN	M3y0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LC-2	NVfGZYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\kSGlEPTB;MU[uNVUxPiEQvF2=	M2mxXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NCI-H1648	NV;XSoFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmW5TWM2OD1zNj6yOVQh\|ryP	MlX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
RL95-2	NWHDSnVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTaTWM2OD1zNj6zPVc5KM7:TR?=	MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
KNS-42	M4rkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MornTWM2OD1zNj63Nlc1KM7:TR?=	M4jqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
RPMI-6666	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorTTWM2OD1zNj65NlEyKM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SIG-M5	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\QOmlEPTB;MUeuNVkxOyEQvF2=	M{K5RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	NXXLbZhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHqTWM2OD1zNz63OFUyKM7:TR?=	MmDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MONO-MAC-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTF5LkmzNVIh\|ryP	M3:2[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LAN-6	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnn4TWM2OD1zOD63OVU4KM7:TR?=	NUmxNWZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
A388	MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoS4TWM2OD1zOT6zNFU6KM7:TR?=	M4r0V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SK-NEP-1	M1Hjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPxd\|BKSzVyPUKwMlIyOzJizszN	M2TqU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
TE-10	NVPLNoJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DUSWlEPTB;MkCuOVIzOSEQvF2=	NVGzTlV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HL-60	M3OzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljRTWM2OD1{MD65NFk6KM7:TR?=	NVzGc2cyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
MC116	NYPPbZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nJR2lEPTB;MkGuO\|IzOSEQvF2=	M3u2d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW962	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEK3T3ZKSzVyPUKxMlc6OTVizszN	M3vRcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
NOMO-1	Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlriTWM2OD1{Mj62OVY1KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CTB-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2m4e2lEPTB;MkKuPFY4OSEQvF2=	MnfEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MRK-nu-1	NWfmUoROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTJ{LkmwO\|Qh\|ryP	M{[2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
GR-ST	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLFcYxKSzVyPUKzMlc3KM7:TR?=	NYnF[o42RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
HH	NGG4NmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJ2LkCwN{DPxE1?	MoS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H1963	M4rlW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPTRnNKSzVyPUK0MlA4QDJizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
QIMR-WIL	M3zLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13EOGlEPTB;MkSuPFc4OiEQvF2=	NVLFVoxiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
CGTH-W-1	M3PFVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEf1e3FKSzVyPUK1MlA4OjNizszN	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LP-1	NVHkTpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPTdFlNUUN3ME2yOU43PTVzIN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
NCI-H748	M1;vR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfFZXRKSzVyPUK2MlUyOzdizszN	NYHYUpR1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
PF-382	NXfHVm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFvSfWdKSzVyPUK3MlIzOjNizszN	M2LFeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ATN-1	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;Q[G5UUUN3ME2yO{4{PzN{IN88US=>	MnrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
L-540	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[3TWM2OD1{Nz62OFU6KM7:TR?=	M1rmeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LXF-289	NX75NWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVH3XZp6UUN3ME2yO{44PTF7IN88US=>	M2HWW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
LS-513	NHLSNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fnUWlEPTB;MkiuNVgxPyEQvF2=	MnX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H1581	NV\ucZdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTNyLkO5O\|Yh\|ryP	M1LMUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
ES6	NVPrOJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzS[odKSzVyPUOwMlY5QTlizszN	M1fZRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
SW982	NEXNdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XhXmlEPTB;M{CuPFU3PiEQvF2=	M2X2d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
DOHH-2	NE\XWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3:wN2lEPTB;M{GuOVg6OyEQvF2=	NEPiS5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
DB	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXxeHVKSzVyPUOzMlk1OzFizszN	M4HBNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
MPP-89	M2PCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIi1SlRKSzVyPUO0MlE4PTZizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LB831-BLC	M3vrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1TVZWlEPTB;M{SuOVE5PCEQvF2=	NHq1bpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NB5	M1nmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTN2Lki1N\|Uh\|ryP	M3rpeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFYxOTdzOT:nQnNCVkeHUkyvZV4>
GB-1	NHewRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLyXnFKSzVyPUO1MlA1PjlizszN	NEDuZZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
TE-15	Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXaTWM2OD1\|NT6yNlM5KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
LC4-1	M3:xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPiRmRKSzVyPUO1MlM5PDdizszN	Ml\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
NCI-H747	NGnOXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTHVZJKSzVyPUO2MlE{PjlizszN	NH;4T3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M2O3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVq2XGllUUN3ME2zPE44OzR5IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SK-MM-2	NHyyeJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXj2eItqUUN3ME20NE4yOTR4IN88US=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
TGW	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2H0OGlEPTB;NEGuNFU3OyEQvF2=	MoX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
ONS-76	MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTR{LkS4PFMh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
CPC-N	NXLsXYRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTR{Lkm5O\|Eh\|ryP	NFWyO2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
ES4	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTR2LkSxOVMh\|ryP	NWDtUG81RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
Daudi	M2HWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHVeVgxUUN3ME20OU4xQDJ5IN88US=>	MkXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
MOLT-4	NFuxWZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG[yNlRKSzVyPUS1MlA5PTNizszN	NFjpd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw3ODF5MUmvK\|5USU6JRWK8M4E,
HT-144	MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M134T2lEPTB;NE[uO\|I3KM7:TR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
SW872	NF\GNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf2UGZVUUN3ME20PE4yQTN\|IN88US=>	MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
D-283MED	NWDSN\|F6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv1NmVxUUN3ME20PE4{PTR{IN88US=>	NWnGOXZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-H2126	M2LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTR6Lki0O\|Yh\|ryP	NVriNIRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPjBzN{G5M{c,W0GQR1XSQE9iRg>?
NCI-SNU-16	M2jpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfv[nNKSzVyPUS5MlIyPDNizszN	MkTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOlAyPzF7Lze+V2FPT0WUPD;hQi=>
CESS	M2TyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHrTWM2OD12OT61NFg5KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+
A101D	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHVU2NKSzVyPUS5Mlk4OzZizszN	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly2NFE4OTlxJ{7TRW5ITVJ:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pALK / pAKT / pERK / pS6; PubMed: 24675041 Cancer Discov H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins. pROS1 / ROS1; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. pSTAT3 / STAT3; PubMed: 25351743 Clin Cancer Res Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins. PARP / cleaved caspase-3 / Bax / Bcl-2; PubMed: 25193856 Oncotarget The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr. p-c-Met / c-Met; PubMed: 25193856 Oncotarget Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification). p-mTOR; PubMed: 26384345 Oncotarget Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.	24675041 25351743 25193856 26384345
Immunofluorescence	LC3 / lysosome; PubMed: 26384345 Oncotarget Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. SRC / Met; PubMed: 26517812 Oncotarget Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively. α-tubulin; PubMed: 26517812 Oncotarget LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm. cytochrome c; PubMed: 25193856 Oncotarget PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red p-ALK; PubMed: 25193856 Oncotarget PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.	26384345 26517812 25193856

In vivo

In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm³) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.^[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.^[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.^[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in ¹⁸F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.^[4]

Protocol

Kinase Assay: ^[1]	- Collapse Cellular kinase phosphorylation ELISA assays: Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na₃VO₄, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H₂SO₄; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research: ^[1]	- Collapse Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells Concentrations: 0-256 nM Incubation Time: 1 hour Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na₃VO₄, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3^′,5,5^′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H₂SO₄; and (f) measured for absorbance in 450 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Female or male nu/nu mice bearing NCI-H441,or DLD-1, or MDA-MB-231 Dosages: 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day Administration: Administered via p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	9 mg/mL (19.98 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+dd H2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Crizotinib (PF-02341066) SDF

Molecular Weight	450.34
Formula	C₂₁H₂₂Cl₂FN₅O
CAS No.	877399-52-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04148066	Recruiting	Diagnostic Test: ctDNA blood sample	Carcinoma Non-Small-Cell Lung	The Netherlands Cancer Institute\|Roche Pharma AG	July 17 2019	Not Applicable
NCT03947385	Recruiting	Drug: IDE196\|Drug: Binimetinib\|Drug: Crizotinib	Metastatic Uveal Melanoma\|Cutaneous Melanoma\|Colorectal Cancer\|Other Solid Tumors	IDEAYA Biosciences	June 28 2019	Phase 1\|Phase 2
NCT03439215	Active not recruiting	Drug: Lorlatinib	Carcinoma Non-Small-Cell Lung	Fondazione Ricerca Traslazionale\|Clinical research technology Srl	June 13 2017	Phase 2
NCT02946216	Unknown status	Genetic: ctDNA analysis	Non-small Cell Lung Cancer Stage III\|Non-Small-Cell Lung Cancer Metastatic\|Adenocarcinoma of Lung\|EGFR Wildtype	First People''s Hospital of Hangzhou	November 2016	--
NCT02511184	Terminated	Drug: Crizotinib\|Drug: Pembrolizumab	ALK-positive Advanced NSCLC	Pfizer\|Merck Sharp & Dohme Corp.	October 2015	Phase 1
NCT02419287	Active not recruiting	Drug: crizotinib	Anaplastic Large Cell Lymphoma ALK-Positive	University of Milano Bicocca	April 2015	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?
Answer:
Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Selective c-Met Inhibitor

PF-04217903 : C-Met-selective, IC50=4.8 nM.
Most Potent c-Met Inhibitor

INCB28060 : C-Met, IC50=0.13 nM.
c-Met Inhibitor in Clinical Trial

Tivantinib (ARQ 197) : Phase III for Hepatocellular Carcinoma.

Related c-Met Products

NPS-1034 ^New

NPS-1034 is a dual Met (c-Met)/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.
Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Bemcentinib (R428) ^New

Bemcentinib (R428, BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
Foretinib (GSK1363089)

Foretinib (GSK1363089, EXEL-2880, XL-880, GSK089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.
Capmatinib (INCB28060)

Capmatinib (INCB28060, INC280, NVP-INC280) is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.

Features:Inactive against RONβ, another member of the c-MET RTK family, as well as EGFR and HER-3 (members of the EGFR RTK family).
Tivantinib (ARQ 197)

Tivantinib (ARQ 197) is the first non-ATP-competitive c-Met inhibitor with K_i of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis. Phase 3.

Features:The first selective c-Met inhibitor to be advanced into human clinical trials.
PHA-665752

PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.
BMS-777607

BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases. Phase 1/2.

Features:A potent inhibitor of the Met family, and >40-fold selectivity vs. Lck, VEGFR2, and TrkA/B and >500-fold selective vs. other receptor and non-receptor kinases.
PF-04217903

PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.
SU11274

SU11274 (PKI-SU11274) is a selective Met (c-Met) inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2. SU11274 induces autophagy, apoptosis and cell cycle arrest.

Choose Your Country or Region

By Signaling Pathways

By product type

Crizotinib (PF-02341066)